2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163996
    DD202-114 2886728-09-0 99.27%
    DD202-114 is a potent and selective GLP1R agonist. DD202-114 inhibits hERG with an IC50 of 15.9 μM. DD202-114 exhibits strong CYP2C8 inhibition with an IC50 of 0.22 μM. DD202-114 promotes cAMP accumulation. DD202-114 reduces blood glucose levels and food intake. DD202-114 has the potential to be used in the study of type 2 diabetes mellitus (T2DM) and obesity.
    DD202-114
  • HY-168894
    CT-1 99.90%
    CT-1 is a secreted protein belonging to the IL-6 cytokine family. Overexpression of CT-1 enhances cell proliferation, migration and angiogenesis via the ADMA/DDAH pathway. CT-1 inhibits the growth of triple-negative breast cancer cells by simultaneously inducing Ferroptosis in N2-type tumor-associated neutrophils and cancer cells. CT-1 activates the Jak/STAT-3, p42/p44 MAPK and AMPK pathways, and inhibits GSK-3β activity through phosphorylation to induce cardiomyocyte hypertrophy. CT-1 enhances the viability of cardiomyocytes and neurons, reduces cell Apoptosis, induces the expression of heat shock proteins (HSP) and BNP, and inhibits TNF levels. CT-1 exerts anti-tumor activity in mouse models of triple-negative breast cancer. CT-1 improves cognitive impairment in mice. CT-1 is applicable to the research of ischemic heart disease, triple-negative breast cancer, myocardial hypertrophy, Parkinson's disease, hypertensive heart disease, myocardial infarction, acute Chagas cardiomyopathy, high-fat diet-induced cognitive impairment and diabetes-related cognitive impairment.
    CT-1
  • HY-170794
    ALT-007 2035010-37-6 99.81%
    ALT-007 is an orally active serine palmitoyltransferase (SPT) inhibitor that selectively reduces the levels of toxic very-long-chain deoxysphingolipids to enhance protein homeostasis. ALT-007 restores aging-related loss of muscle mass in a mouse model of sarcopenia. ALT-007 enhances protein homeostasis in both mouse and C. elegans models of aging and disease. ALT-007 can be used for age-related neuromuscular diseases research.
    ALT-007
  • HY-173527
    PSSI-51 99.75%
    PSSI-51 is an orally active, peripherally selective inhibitor of succinyl-CoA:3-ketoacid-CoA transferase (SCOT). PSSI-51 inhibits SCOT activity in peripheral tissues (such as muscle and kidney) but does not affect SCOT activity in brain tissue. PSSI-51 reduces ketone body oxidation by inhibiting SCOT, thereby improving obesity-related hyperglycemia. PSSI-51 can be used in the study of type 2 diabetes (T2D) and has the potential to improve obesity-related metabolic disorders.
    PSSI-51
  • HY-177850
    ACSL5-IN-3 3098298-22-4 99.74%
    ACSL5-IN-3 (page 115 line 11) is an ACSL5 inhibitor. ACSL5-IN-3 can be used for research of tumours, digestive system diseases, and endocrine and metabolic diseases.
    ACSL5-IN-3
  • HY-179738
    CTR/AMYR modulator-1 3097482-67-9 99.71%
    CTR/AMYR modulator-1 is a calcitonin receptor/amylin receptor modulator. CTR/AMYR modulator-1 can be used for the research of metabolic disease.
    CTR/AMYR modulator-1
  • HY-186096
    LP-856866 99.92%
    LP-856866 is an orally active ACSL5 inhibitor, with IC50 values of 8 nM and 4 nM against mouse and human ACSL5, respectively, and IC50 values of 6 nM and 17 nM against mouse and human ACSL1, respectively. LP-856866 induces delayed gastric emptying, promotes GLP-1 release, reduces food intake, decreases body weight and body fat mass, preserves lean body mass, improves glucose homeostasis, enhances insulin sensitivity, reduces hepatic lipid accumulation, and lowers serum triglyceride and total cholesterol levels. LP-856866 is applicable to research on diet-induced obesity.
    LP-856866
  • HY-41417R
    Octanoic acid (Standard) 124-07-2 98.95%
    Octanoic acid (Standard) is the analytical standard of Octanoic acid. This product is intended for research and analytical applications. Octanoic acid (Caprylic acid) is an oily liquid with a slightly unpleasant rancid taste and used commercially in the production of esters used in perfumery and also in the manufacture of dyes.
    Octanoic acid (Standard)
  • HY-B0093A
    Benazepril hydrochloride 86541-74-4 99.96%
    Benazepril (CGS14824A) hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy.
    Benazepril hydrochloride
  • HY-B0589S
    Atorvastatin-d5 hemicalcium 222412-82-0 99.00%
    Atorvastatin-d5 (hemicalcium) is the deuterium labeled Atorvastatin. Atorvastatin hemicalcium is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
    Atorvastatin-d5 hemicalcium
  • HY-B1451A
    Imidapril 89371-37-9 99.0%
    Imidapril (TA-6366 free base) is an orally active dual inhibitor of angiotensin-converting enzyme (ACE) and MMP-9. Imidapril inhibits lipopolysaccharide-induced phosphorylation of c-Jun, MKK4 and JNK in monocytes, and downregulates the production of specific inflammatory factors such as TNF-α and IP-10, thereby exerting anti-inflammatory activity. Imidapril also effectively ameliorates mesangial expansion and reduces urinary albumin excretion by inhibiting angiotensin AngII production, lowering glomerular pressure and oxidative stress, thus delaying disease progression. Imidapril can also directly bind to the active site of MMP-9 to inhibit gelatinase activity, and suppress the enlargement of cerebral aneurysms without altering systemic blood pressure. Imidapril is widely applicable to related studies on autoimmune glomerulonephritis, diabetic nephropathy, cerebral aneurysms and other conditions.
    Imidapril
  • HY-E70135
    Endo-β-N-acetylglucosaminidase F1 37278-88-9
    Endo-β-N-acetylglucosaminidase F1 (Endo F1) cleaves Asparagine-linked high mannose and some hybrid oligosaccharides.
    Endo-β-N-acetylglucosaminidase F1
  • HY-N0169R
    Hyodeoxycholic acid (Standard) 83-49-8 99.61%
    Hyodeoxycholic acid (Standard) is the analytical standard of Hyodeoxycholic acid. This product is intended for research and analytical applications. Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHO cells.
    Hyodeoxycholic acid (Standard)
  • HY-N0181A
    Lumisterol 474-69-1 99.41%
    Lumisterol (9β,10α-Ergosterol), a steroid compound, is the (9β,10α)-stereoisomer of Ergosterol (HY-N0181). Lumisterol is a photoprotective agent against UVB-induced DNA damage and anti-proliferative activities.
    Lumisterol
  • HY-N0351A
    cis-p-Coumaric acid 4501-31-9 98.33%
    cis-p-Coumaric acid (cis-4-Hydroxycinnamic acid) is the cis-form of p-Coumaric acid (HY-N0351), which is higher in viable seeds of groundnuts than in non-viable ones. p-Coumaric acid is an isomer of cinnamic acid with oral activity. p-Coumaric acid inhibits cell proliferation and promotes Apoptosis.
    cis-p-Coumaric acid
  • HY-N0729R
    Linoleic acid (Standard) 60-33-3 99.68%
    Linoleic acid (Standard) is the analytical standard of Linoleic acid (HY-N0729). This product is intended for research and analytical applications. Linoleic acid is a common polyunsaturated (PUFA) found in plant-based oils, nuts and seeds. Linoleic acid is a part of membrane phospholipids, and functions as a structural component to maintain a certain level of membrane fluidity of the transdermal water barrier of the epidermis. Linoleic acid induces red blood cells and hemoglobin damage via oxidative mechanism .
    Linoleic acid (Standard)
  • HY-N11416
    Glycodehydrocholic acid 3415-45-0 99.90%
    Glycodehydrocholic acid is a bile acid glycine conjugate. Glycodehydrocholic acid is used to diagnose cancer and other diseases.
    Glycodehydrocholic acid
  • HY-N14035
    Garcinia cambogia extract 90045-23-1
    Garcinia cambogia extract is an orally active anti-obesity agent. Garcinia cambogia extract upregulates the gene expression of aP2, SREBP1c, PPARγ2 and C/EBPα. Garcinia cambogia extract reduces the rate of body weight gain, visceral fat accumulation, lipid levels in blood and liver, as well as plasma insulin and leptin levels. Garcinia cambogia extract ameliorates high-fat diet-induced obesity.
    Garcinia cambogia extract
  • HY-P10032
    NN1177 99.54%
    NN1177 is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice.
    NN1177
  • HY-P11474
    FZ1 peptide 99.92%
    FZ1 peptide is an integrin αvβ3 agonist. FZ1 peptide binds to integrin αvβ3, effectively activates FAK, FAK-dependent AKT and ERK1/2 signaling pathways. FZ1 peptide enhances VEGFC-induced endothelial angiogenesis, accelerates diabetic skin wound healing.
    FZ1 peptide
Cat. No. Product Name / Synonyms Application Reactivity